ANI Pharmaceuticals offers an asymmetric opportunity in small-cap pharma, with a niche in generics, rare disease treatments, ...

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Sovereign Wealth Fund. In this ...

A quirk in the website OpenSecrets has given RFK Jr. a chance to misleadingly portray Sen. Bernie Sanders as receiving big ...

Despite the death of its golden goose, AbbVie expects to achieve high single-digit compound annual sales growth to the end of ...

“Companies are realizing that investing stateside can provide more control and resilience to the drug supply chain,” says Dymowski. She cites political tensions, import and export disruptions, and ...

Top Republican recipients of contributions from employees or PACS associated with the pharmaceutical/health products ...

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been ...

However, P V Appaji, former director general of Pharmexcil finds that the interest of Indian companies to get approvals for ...

Shares of AstraZeneca Pharma India Ltd closed at ₹7,450 on the BSE, down 1.29% ahead of the earnings announcement.